© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
March 04, 2021
More patients also achieved endoscopic and histologic remission in the treatment group compared to the placebo group.
February 25, 2021
The findings should assuage concerns about small intestinal bacterial overgrowth when prescribing treatment with proton pump inhibitors.
February 22, 2021
In the U-ACCOMPLISH study, 37% of patients treated with upadacitinib achieved histologic-endoscopic mucosal improvement at week 8.
February 09, 2021
Crohn’s disease patients and ulcerative colitis patients showed changes in energetic metabolism in plasma and biopsy samples compared to a control group.
January 31, 2021
Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.
January 21, 2021
A related editorial noted the study authors’ numbers were higher than those of the Mayo Clinic.
January 20, 2021
About half of patients experienced adverse events, and two-thirds of those events were likely related to inflammatory bowel disease medications.
December 09, 2020
Approximately 30% of patients treated with upadacitinib achieved endoscopic mucosal improvement at week 8, compared to just 7% of the placebo group
December 04, 2020
This combination therapy may have a few advantages over standard corticosteroid regimens.
December 03, 2020
Despite the difficult circumstances, experts believe colorectal cancer rates will not decrease in the coming years due to delays in screenings.